Toshinari Yamashita - Concepedia

Author

Toshinari Yamashita

Kanagawa Prefectural Hospital Organization ORCID

Also Known As

Nobuko Kawaguchi, T Szabo Yamashita, T YAMASHITA, T Yamashita, T. Yamashita, TOSHINARI YAMASHITA, Takanori YAMASHITA, Toshinari YAMASHITA, Toshinari Yamashita, Vittoria Fotia

267

Publications

10.7K

Citations

H-Index

108

Concepts

All Affiliations

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center Aichi Cancer Center Daiichi Sankyo (United States)Tokyo Metropolitan Komagome Hospital

About

Toshinari Yamashita is an author at Kanagawa Prefectural Hospital Organization specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	38	1.3K
2	Health Sciences	9	9	269
3	Engineering	3	3	95
4	Natural Sciences	1	1	83
5	Public Health	1	1	46

Toshinari Yamashita

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Fabrice André, Eva Ciruelos, Gábor Rubovszky, New England Journal of Medicine	2019	2.4K
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi, William Jacot, Toshinari Yamashita, New England Journal of Medicine	2022	2.3K
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi, Cristina Saura, Toshinari Yamashita, New England Journal of Medicine	2019	1.9K
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 Fabrice André, Eva Ciruelos, Dejan Juric, Annals of Oncology	2020	557
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer Hope S. Rugo, Fabrice André, Toshinari Yamashita, Annals of Oncology	2020	175
One-carbon metabolism-related gene polymorphisms and risk of breast cancer Takeshi Suzuki, Keitaro Matsuo, Kaoru Hirose, Carcinogenesis	2008	123
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study Hope S. Rugo, Joyce O’Shaughnessy, F Boyle, Annals of Oncology	2022	109
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse Saiko Kurosawa, T Yamaguchi, S Miyawaki, Haematologica	2010	107
Five-year follow-up study of patients with persistent vegetative state K Higashi, Makoto Hatano, S Abiko, Journal of Neurology Neurosurgery & Psychiatry Clinical SymptomsFunctional RecoveryRehabilitationSurgeryPersistent Vegetative State	1981	99

Page 1